Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Cancer statistics, 2016

Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817 · see citing works

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,355 · see citing works

Trastuzumab-Induced Hepatotoxicity: A Case Report

Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432 · see citing works

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,015 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860 · see citing works

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Smith, I., Procter, M. J., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,503 · see citing works

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J. D., Goel, N. J., Aronson, A. B., Li, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 870 · see citing works

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Kaufman, B., Mackey, J. R., Clemens, M., Bapsy, P. P., Vaid, A. K., Wardley, A. M., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 842 · see citing works

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 721 · see citing works

Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA

Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · cited 1× · see citing works

Extending Survival with Chemotherapy in Metastatic Breast Cancer

O’Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 669 · see citing works

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 642 · see citing works

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gökmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 563 · see citing works

The Distinctive Nature of HER2-Positive Breast Cancers

Burstein, H. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058197 · Cited by 541 · see citing works

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Burstein, H. J., Sun, Y. P., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A. H., Ranade, A. A., Jiao, S., Schwartz, G. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522 · see citing works

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

Robert, N. J., Leyland-Jones, B. R., Asmar, L., Belt, R. J., Ilegbodu, D., Loesch, D. M., Raju, R. N., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479 · see citing works

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, S. E., Narasanna, A., Pérez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G. F., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 474 · see citing works

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C. K. H., Sidlofsky, S., Pritzker, K., Hartwick, R. W. J., Hanna, W. M., Lickley, L. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1340 · Cited by 441 · see citing works

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343 · see citing works

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.

Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. C. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327 · see citing works

Genomic Characterization of Primary Invasive Lobular Breast Cancer

Desmedt, C., Zoppoli, G. M., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., Fumagalli, D., Brown, D. N., Rothé, F., Vincent, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0334 · Cited by 316 · see citing works

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Tsou, H., Overbeek, E., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C. M., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 302 · see citing works

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Wong, K.-K., Fracasso, P. M., Bukowski, R. M., Lynch, T. J., Münster, P. N., Shapiro, G. I., Janne, P. A., Eder, J. P., Naughton, M. J., Ellis, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1978 · Cited by 301 · see citing works

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Greulich, H. E., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K., Yun, C., Zhang, X., Lee, S., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 279 · see citing works

Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer

Schwartzberg, L. S., Franco, S. X., Florance, A. M., O’Rourke, L., Maltzman, J., & Johnston, S. R. D. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0240 · Cited by 186 · see citing works

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

Marcom, P. K., Isaacs, C. J., Harris, L. N., Wong, Z. W., Kommareddy, A., Novielli, N., Mann, G., Tao, Y., & Ellis, M. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9307-8 · Cited by 154 · see citing works

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

Martín, M., Bonneterre, J. M., Geyer, C. E., Ito, Y., Ro, J., Láng, I., Kim, S., Germa, C., Vermette, J. J., Wang, K., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.142 · Cited by 152 · see citing works

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

Kancha, R. K., von Bubnoff, N. C. C., Bartosch, N., Peschel, C., Engh, R. A., & Duyster, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026760 · Cited by 140 · see citing works

Relapsed Classic E-Cadherin ( <i>CDH1</i> )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of <i>HER2</i> ( <i>ERBB2</i> ) Gene Mutations

Ross, J. S., Wang, K., Sheehan, C. E., Boguniewicz, A. B., Otto, G., Downing, S. R., Sun, J., He, J., Curran, J. A., Ali, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0295 · Cited by 135 · see citing works

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R. J., Lanman, R. B., Berger, M. F., Hyman, D. M., Solit, D. B., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1431 · Cited by 99 · see citing works

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

Ross, J. S., Ali, S. M., Wang, K., Khaira, D., Palma, N. A., Chmielecki, J., Palmer, G. A., Morosini, D., Elvin, J. A., Fernandez, S. V., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3592-z · Cited by 96 · see citing works

Profile of neratinib and its potential in the treatment of breast cancer

Kong, A. H., & Feldinger, K. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s54414 · Cited by 93 · see citing works

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor

Ben-Baruch, N. E., Bose, R., Kavuri, S. M., Ma, C. X., & Ellis, M. J. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0131 · Cited by 79 · see citing works

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers

Wen, W., Chen, W., Xiao, N., Bender, R. P., Ghazalpour, A., Tan, Z., Swensen, J. J., Millis, S. Z., Basu, G. D., Gatalica, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.04.003 · Cited by 76 · see citing works

Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

Rexer, B. N., Ghosh, R., Narasanna, A., Estrada, M. V., Chakrabarty, A., Song, Y., Engelman, J. A., & Arteaga, C. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1038 · Cited by 73 · see citing works

New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available

Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 65 · see citing works

Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy

Ali, S. M., Alpaugh, R. K., Downing, S. R., Stephens, P. J., Yu, J. Q., Wu, H. G., Buell, J. K., Miller, V. A., Lipson, D., Palmer, G. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.0599 · Cited by 45 · see citing works

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation

Chumsri, S., Weidler, J. M., Ali, S. M., Balasubramanian, S., Wallweber, G. J., Eli, L. D., Chenna, A., Huang, W., DeRidder, A. M., Goicocheal, L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0132 · Cited by 42 · see citing works

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

Boulbés, D. R., Arold, S. T., Chauhan, G. B., Blachno, K. V., Deng, N., Chang, W., Jin, Q., Huang, T.-H., Hsu, J.-M., Brady, S. W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.011 · Cited by 41 · see citing works

Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study

Ross, J. S., Gay, L. M., Nozad, S., Wang, K., Ali, S. M., Boguniewicz, A. B., Khaira, D., Johnson, A., Elvin, J. A., Vergilio, J., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3682-6 · Cited by 22 · see citing works

A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy

Grellety, T., Soubeyran, I., Robert, J., Bonnefoi, H. R., & Italiano, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv496 · Cited by 13 · see citing works

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P. L., Hanna, W. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,449 · see citing works

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P. L., Hanna, W. M., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,480 · see citing works

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780 · see citing works

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

Odegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., Fairclough, S. R., Zill, O. A., Sikora, M., Mokhtari, R. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3831 · Cited by 437 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Meric‐Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J. A., & Piha-Paul, S. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 345 · see citing works

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Russano, M., Napolitano, A., Ribelli, G., Iuliani, M., Simonetti, S., Citarella, F., Pantano, F., Dell’Aquila, E., Anesi, C., Silvestris, N., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01601-2 · Cited by 260 · see citing works

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242 · see citing works

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 228 · see citing works

Cancer gene mutation frequencies for the U.S. population

Mendiratta, G., Ke, E., Aziz, M., Liarakos, D., Tong, M. M., & Stites, E. C. (2021) · Nature Communications · doi:10.1038/s41467-021-26213-y · Cited by 208 · see citing works

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 203 · see citing works

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 197 · see citing works

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

Reed, A. E. M., Kalinowski, L., Simpson, P. T., & Lakhani, S. R. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01384-6 · Cited by 193 · see citing works

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Choong, G. M. Y., Cullen, G. D., & O'Sullivan, C. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21634 · Cited by 178 · see citing works

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 178 · see citing works

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Pegram, M. D., Jackisch, C., & Johnston, S. R. D. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00533-2 · Cited by 157 · see citing works

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortés, J., Hyman, D., Juric, D., Krop, I. E., Bièche, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz036 · Cited by 151 · see citing works

Neratinib: First Global Approval

Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0811-4 · Cited by 148 · see citing works

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

Hrebien, S., Citi, V., García-Murillas, I., Cutts, R., Fenwick, K., Kozarewa, I., McEwen, R. K., Ratnayake, J., Maudsley, R., Carr, T. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz085 · Cited by 146 · see citing works

Treatment of advanced HER2-positive breast cancer: 2018 and beyond

Ponde, N. F., Brandão, M., El-Hachem, G., Werbrouck, E., & Piccart, M. J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.016 · Cited by 143 · see citing works

HER2-positive breast cancer: Current and new therapeutic strategies

Escrivá-de-Romaní, S., Arumí, M., Bellet, M., & Saura, C. (2018) · The Breast · doi:10.1016/j.breast.2018.03.006 · Cited by 132 · see citing works

Genomic alterations of ERBB receptors in cancer: clinical implications

Mishra, R., Hanker, A. B., & Garrett, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.22825 · Cited by 129 · see citing works

The prognostic effects of somatic mutations in ER-positive breast cancer

Griffith, O. L., Spies, N. C., Anurag, M., Griffith, M., Luo, J. R., Tu, D., Yeo, B. J., Kunisaki, J., Miller, C. A., Krysiak, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05914-x · Cited by 131 · see citing works

HER2-positive advanced breast cancer treatment in 2020

Cesca, M. G., Vian, L., Cristóvão‐Ferreira, S., Ponde, N. F., & de Azambuja, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102033 · Cited by 127 · see citing works

Liquid Biopsy in Breast Cancer: A Focused Review

Tay, T. K. Y., & Tan, P. H. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0559-ra · Cited by 119 · see citing works

Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

Buono, G., Gerratana, L., Bulfoni, M., Provinciali, N., Basile, D., Giuliano, M., Corvaja, C., Arpino, G., Mastro, L. D., Placido, S. D., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.01.004 · Cited by 116 · see citing works

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer

Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 108 · see citing works

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Croessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 107 · see citing works

Co-Occurring Gain-of-Function Mutations in HER2 and HER3 Modulate HER2/HER3 Activation, Breast Cancer Progression, and HER2 Inhibitor Sensitivity

Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C. A., Akamatsu, H., Lee, K., Chatterjee, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 104 · see citing works

Role of ctDNA in Breast Cancer

Sant, M., Bernat‐Peguera, A., Felip, E., & Vila, M. M. (2022) · Cancers · doi:10.3390/cancers14020310 · Cited by 102 · see citing works

Molecular profiling and molecular classification of endometrioid ovarian carcinomas

Cybulska, P., Paula, A. D. C., Tseng, J. H., Leitão, M. M., Bashashati, A., Huntsman, D. D., Nazeran, T. M., Aghajanian, C. A., Abu‐Rustum, N. R., DeLair, D. F., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.07.012 · Cited by 101 · see citing works

Variant allele frequency: a decision-making tool in precision oncology?

Bielo, L. B., Trapani, D., Repetto, M., Crimini, E., Valenza, C., Belli, C., Criscitiello, C., Marra, A., Subbiah, V., & Curigliano, G. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.011 · Cited by 94 · see citing works

Prevalence and role of HER2 mutations in cancer

Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 89 · see citing works

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

Pairawan, S. S., Hess, K. R., Jankú, F., Sánchez, N., Shaw, K. R. M., Eng, C., Damodaran, S., Javle, M. M., Kaseb, A. O., Hong, D. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0306 · Cited by 85 · see citing works

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Abraham, J., Montero, A. J., Jankowitz, R. C., Salkeni, M. A., Beumer, J. H., Kiesel, B. F., Piette, F., Adamson, L. M., Nagy, R. J., Lanman, R. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00858 · Cited by 78 · see citing works

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

Gaibar, M., Beltrán, L., Romero‐Lorca, A., Fernández‐Santander, A., & Novillo, A. (2020) · Journal of Oncology · doi:10.1155/2020/6375956 · Cited by 81 · see citing works

Liquid biopsies and cancer omics

Amelio, I., Bertolo, R. G., Bove, P., Buonomo, O. C., Candi, E., Chiocchi, M., Cipriani, C., Daniele, N. D., Ganini, C., Juhl, H. H., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00373-0 · Cited by 78 · see citing works

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors

Thompson, J. C., Scholes, D. G., Carpenter, E. L., & Aggarwal, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02445-1 · Cited by 78 · see citing works

High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2

Nagano, M., Kohsaka, S., Ueno, T., Kojima, S., Saka, K., Iwase, H., Kawazu, M., & Mano, H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0991 · Cited by 76 · see citing works

Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways

Pareja, F. G., Geyer, F. C., Kumar, R., Selenica, P., Piscuoglio, S., Ng, C. K. Y., Burke, K. A., Edelweiss, M., Murray, M. P., Brogi, E., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0042-6 · Cited by 78 · see citing works

The mutational landscape of the SCAN‐B real‐world primary breast cancer transcriptome

Brueffer, C., Gladchuk, S., Winter, C., Vallon‐Christersson, J., Hegardt, C., Häkkinen, J., George, A. M., Chen, Y., Ehinger, A., Larsson, C., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012118 · Cited by 74 · see citing works

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Caputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 77 · see citing works

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Oaknin, A., Friedman, C. F., Roman, L. D., D'souza, A., Braña, I., Bidard, F., Goldman, J. W., Alvarez, E. A., Boni, V., ElNaggar, A. C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.025 · Cited by 73 · see citing works

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Jhaveri, K. L., Eli, L. D., Wildiers, H. P. M. W., Hurvitz, S. A., Zotano, Á. G., Unni, N. G., Brufsky, A., Park, H., Waisman, J. R., Yang, E. S.-H., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.003 · Cited by 74 · see citing works

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

Yi, Z., Rong, G., Guan, Y., Li, J., Chang, L., Li, H., Liu, B., Wang, W., Guan, X., Ouyang, Q., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00201-9 · Cited by 70 · see citing works

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 68 · see citing works

Landscape of circulating tumour DNA in metastatic breast cancer

Davis, A. A., Jacob, S. L., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., Platanias, L. C., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102914 · Cited by 69 · see citing works

Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing

Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00713-0 · Cited by 66 · see citing works

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Darrigues, L., Pierga, J., Bernard‐Tessier, A., Bièche, I., Silveira, A. B., Michel, M., Loirat, D., Cottu, P. H., Cabel, L., Dubot, C., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01411-0 · Cited by 63 · see citing works

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Ma, C. X., Luo, J., Freedman, R. A., Pluard, T. J., Nangia, J. R., Lu, J., Valdez-Albini, F., Cobleigh, M., Jones, J. M., Lin, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3418 · Cited by 59 · see citing works

Neratinib for HER2-positive breast cancer with an overlooked option

Guo, L., Shao, W., Zhou, C., Yang, H. J., Yang, L., Cai, Q., Wang, J., Shi, Y., Huang, L., & Zhang, J. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00736-0 · Cited by 59 · see citing works

Precision medicine in breast cancer: From clinical trials to clinical practice

Crimini, E., Repetto, M., Aftimos, P. G., Botticelli, A., Marchetti, P., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102223 · Cited by 56 · see citing works

Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer

Gerratana, L., Davis, A. A., Zhang, Q., Basile, D., Rossi, G., Strickland, K. S., Franzoni, A., Allegri, L., Mu, Z., Zhang, Y., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00345 · Cited by 54 · see citing works

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer

Jacob, S. L., Davis, A. A., Gerratana, L., Velimirovic, M., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1566 · Cited by 55 · see citing works

An update of new small-molecule anticancer drugs approved from 2015 to 2020

Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113473 · Cited by 53 · see citing works

Omics Technologies Improving Breast Cancer Research and Diagnostics

Orsini, A., Diquigiovanni, C., & Bonora, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612690 · Cited by 52 · see citing works

The molecular tumor burden index as a response evaluation criterion in breast cancer

Yi, Z., Ma, F., Rong, G., Liu, B., Guan, Y., Li, J., Sun, X., Wang, W., Guan, X., Mo, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00662-9 · Cited by 53 · see citing works

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL

Wulfkuhle, J. D., Yau, C. S. F., Wolf, D. M., Vis, D. J., Gallagher, R. I., Swigart, L. B., Hirst, G. L., Voest, E. E., DeMichele, A. M., Hylton, N. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00024 · Cited by 51 · see citing works

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Nagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 51 · see citing works

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Freelander, A., Brown, L. J., Parker, A. J., Segara, D., Portman, N., Lau, B., & Lim, E. (2021) · Genes · doi:10.3390/genes12020285 · Cited by 50 · see citing works

Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers

Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49 · see citing works

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020

Liang, X., Yang, Q., Wu, P., He, C., Yin, L., Xu, F., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105011 · Cited by 49 · see citing works

Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing

Yan, Y. H., Chen, S. X., Cheng, L. Y., Rodriguez, A. Y., Tang, R., Cabrera, K., & Zhang, D. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-91142-1 · Cited by 47 · see citing works

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

Sivakumar, S., Jin, D. X., Tukachinsky, H., Murugesan, K., McGregor, K., Danziger, N. A., Pavlick, D. C., Gjoerup, O. V., Ross, J. S., Harmon, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35245-x · Cited by 47 · see citing works

Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies

Shatsky, R. A., Parker, B. A., Bui, N. Q., Helsten, T. L., Schwab, R. B., Boles, S. G., & Kurzrock, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1038 · Cited by 44 · see citing works

Metabolite profiling of human blood by surface-enhanced Raman spectroscopy for surgery assessment and tumor screening in breast cancer

Lin, D., Wang, Y., Wang, T., Zhu, Y., Lin, X., Lin, Y., & Feng, S. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02391-4 · Cited by 41 · see citing works

Liquid biopsy: Cell-free DNA based analysis in breast cancer

Venetis, K., Cursano, G., Pescia, C., D’Ercole, M., Porta, F. M., Blanco, M. C., Frascarelli, C., Ivanova, M. D., Guerini‐Rocco, E., & Fusco, N. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100002 · Cited by 40 · see citing works

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer

Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40 · see citing works

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38 · see citing works

Long noncoding RNA HOTAIR regulates the stemness of breast cancer cells via activation of the NF-κB signaling pathway

Wang, J., Liu, X., Li, P., Wang, J., Shu, Y., Zhong, X., Gao, Z., Yang, J., Jiang, Y., Zhou, X., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102630 · Cited by 34 · see citing works

Targeting HER2 genomic alterations in non-small cell lung cancer

Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 35 · see citing works

Molecular Testing in Breast Cancer

Sun, L., Wu, A. S.-H., Bean, G. R., Hagemann, I. S., & Lin, C. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.07.026 · Cited by 36 · see citing works

ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profiling

Christgen, M., Bartels, S., Radner, M., Raap, M., Rieger, L., Christgen, H., Gluz, O., Nitz, U. A., Harbeck, N., Lehmann, U., et al. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22716 · Cited by 32 · see citing works

The potential of ctDNA analysis in breast cancer

Tzanikou, E., & Lianidou, E. S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1670615 · Cited by 33 · see citing works

Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 33 · see citing works

Challenges and prospects in HER2-positive breast cancer-targeted therapy

Li, X., Zhang, X., Yin, S., & Nie, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104624 · Cited by 36 · see citing works

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

Liu, B., Yi, Z., Guan, Y., Ouyang, Q., Li, C., Guan, X., Lv, D., Li, L., Zhai, J., Qian, H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4652 · Cited by 35 · see citing works

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Medford, A. J., Dubash, T. D., Juric, D., Spring, L. M., Niemierko, A., Vidula, N., Peppercorn, J. M., Isakoff, S. J., Reeves, B. A., LiCausi, J. A., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0090-5 · Cited by 32 · see citing works

Neratinib in HER2-Positive Breast Cancer Patients

Paranjpe, R., Basatneh, D., Tao, G., Angelis, C. D., Noormohammed, S., Ekinci, E., Abughosh, S., Ghose, R., & Trivedi, M. V. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028018824088 · Cited by 31 · see citing works

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance

Bose, R., & Ma, C. X. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2110552 · Cited by 25 · see citing works

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Marín, A., Mamun, A. A., Patel, H. M., Akamatsu, H., Ye, D., Sudhan, D. R., Eli, L. D., Marcelain, K., Brown, B. P., Meiler, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3617 · Cited by 29 · see citing works

Genomic Alteration in Metastatic Breast Cancer and Its Treatment

Li, A., Schleicher, S. M., André, F., & Mitri, Z. I. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280463 · Cited by 26 · see citing works

Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis

Ivanova, E., Ward, A., Wiegmans, A. P., & Richard, D. J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00134 · Cited by 26 · see citing works

The Alterations and Potential Roles of MCMs in Breast Cancer

Liu, X., Liu, Y., Wang, Q., Song, S., Feng, L., & Shi, C. (2021) · Journal of Oncology · doi:10.1155/2021/7928937 · Cited by 26 · see citing works

Extramammary Paget’s disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies

Maeda, T., Kitamura, S., Nishihara, H., & Yanagi, T. (2020) · Oncogene · doi:10.1038/s41388-020-01404-x · Cited by 27 · see citing works

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management

Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2023) · Cancers · doi:10.3390/cancers15225463 · Cited by 25 · see citing works

Review ctDNA and Breast Cancer

Clatot, F. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_12 · Cited by 25 · see citing works

Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer

Liu, M., MacKay, M. J., Kase, M., Piwowarczyk, A., Lo, C., Schaeffer, J., Finkle, J. D., Mason, C. E., Beaubier, N. T., Blackwell, K., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00321 · Cited by 24 · see citing works

Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer

Liao, H., & Li, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s249041 · Cited by 22 · see citing works

The Role of HER2 Status in the Biliary Tract Cancers

Ayasun, R., Özer, M., & Şahin, İ. (2023) · Cancers · doi:10.3390/cancers15092628 · Cited by 22 · see citing works

Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib

Ulaner, G. A., Saura, C., Piha-Paul, S. A., Mayer, I. A., Quinn, D. I., Jhaveri, K. L., Stone, B., Shahin, S., Mann, G., Dujka, M. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1658 · Cited by 21 · see citing works

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib

Shishido, S. N., Masson, R., Xu, L., Welter, L. M., Prabakar, R. K., Souza, A. D., SPICER, D. V., Kang, I. M., Jayachandran, P., Hicks, J. B., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00390-5 · Cited by 21 · see citing works

Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers

Wu, X., Huang, S., He, W., & Song, M. L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110602 · Cited by 22 · see citing works

Recent technologies enhancing the clinical utility of circulating tumor DNA

Manoharan, A., Ravikumar, S., & Bhat, V. B. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.08.010 · Cited by 20 · see citing works

Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2

Riecke, K., & Witzel, I. (2020) · Breast Care · doi:10.1159/000510998 · Cited by 20 · see citing works

Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

Tao, Z., Li, S. X., Shen, K., Zhao, Y., Zeng, H., & Ma, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0719-0 · Cited by 19 · see citing works

HER2 mutation as an emerging target in advanced breast cancer

Bon, G., Lisa, F. S. D., Filomeno, L., Arcuri, T., Krasniqi, E., Pizzuti, L., Barba, M., Messina, B., Schiavoni, G., Sanguineti, G., et al. (2024) · Cancer Science · doi:10.1111/cas.16148 · Cited by 18 · see citing works

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer

Kalra, R., Chen, C. H., Wang, J., Salam, A. B., Dobrolecki, L. E., Lewis, A. N., Sallas, C., Yates, C. C., Gutiérrez, C., Karanam, B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3106 · Cited by 18 · see citing works

Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report

Yan, F., Rinn, K. J., Kullnat, J. A., Wu, A., Ennett, M. D., Scott, E. L., & Kaplan, H. G. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7006 · Cited by 19 · see citing works

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Sturgill, E. G., Misch, A., Lachs, R., Jones, C. C., Schlauch, D., Jones, S. F., Shastry, M., Yardley, D. A., Burris, H. A., Spigel, D. R., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00469 · Cited by 17 · see citing works

Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)

Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G. G., Winer, E. P., Naughton, M., Goetz, M. P., Russell, C. A., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct011 · Cited by 3 · see citing works

Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).

Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Pegram, M. D., Blackwell, K., Bedard, P. L., Hayes, D. F., Goetz, M. P., Niravath, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.516 · Cited by 16 · see citing works

Efficacy and Genomic Analysis of HER2 -Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Jhaveri, K. L., Eli, L. D., Hurvitz, S. A., Brufsky, A., Bose, R., de Miguel, M., Unni, N. G., Reid, S., Quinn, D. I., Mahalingam, D., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4135 · Cited by 4 · see citing works

Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER

Ma, C. X., Luo, J. R., Freedman, R. A., Pluard, T., Nangia, J. R., Lu, J. M., Valdez-Albini, F., Cobleigh, M., Jones, J. M., Lin, N., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-ct026 · Cited by 3 · see citing works

Abstract P1-09-26: Genomic analysis of circulating tumor DNA (ctDNA) from patients with triple-negative, HER2-mutant metastatic breast cancer treated with neratinib as monotherapy or in combination with trastuzumab in the SUMMIT trial

Jhaveri, K. L., Waisman, J. R., Hurvitz, S. A., Brufsky, A., Ma, C. X., de Miguel, M., Evron, E., Unni, N. G., Trédan, O., Malingham, D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1557-3265.sabcs24-p1-09-26